AstraZeneca PLC (LON:AZN) Given Consensus Rating of “Moderate Buy” by Analysts

AstraZeneca PLC (LON:AZN) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 7,935.67 ($98.80).

Several brokerages recently weighed in on AZN. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.74) price target on shares of AstraZeneca in a research report on Monday. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($174.30) target price on shares of AstraZeneca in a report on Friday, November 22nd. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th.

AstraZeneca Stock Performance

LON:AZN opened at £112.32 ($139.84) on Thursday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market cap of £174.10 billion, a price-to-earnings ratio of 3,565.71, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1 year low of GBX 9,461 ($117.79) and a 1 year high of £133.88 ($166.68). The stock’s 50 day simple moving average is £106.13 and its two-hundred day simple moving average is £115.32.

Insider Buying and Selling at AstraZeneca

In related news, insider Tony Mok bought 1,500 shares of AstraZeneca stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of £126.80 ($157.87) per share, with a total value of £190,200 ($236,802.79). Also, insider Pascal Soriot purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were bought at an average cost of £102.03 ($127.03) per share, with a total value of £2,040,600 ($2,540,587.65). Company insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.